MRNA vs VIVS
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 31, 2026
MRNA
VIVS
Investment Advisor Scores
VIVS
Oct 31, 2026AI Analyst Insights
Detailed Metrics Comparison
| Metric | MRNA | VIVS | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 23.0415 | 0 | Tie |
| PEG Ratio | 0 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 2.1% | -51.4% | MRNA |
| Earnings Growth | -85.1% | 0.0% | VIVS |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 52.8/100 | 68.7/100 | VIVS |
| Profit Margin | -141.4% | 0.0% | VIVS |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
| Implied Volatility | N/A | N/A | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | STRONG BUY | VIVS |
Relative Price Performance (Last 90 Days)
Current Technical Phase
MRNA
MarkupPrice above SMA50, rising 50-day trend (47.6% over 20 days), RSI 57
VIVS
MarkdownPrice below a falling SMA50 (slope -24.5%), weak momentum, RSI 37
Fundamentals Snapshot
| Metric | MRNA | VIVS |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -45.3 | 0.0 |
| Trailing P/E | — | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | -0.5% |
| Gross Margin | -0.7% | -37.6% |
| Operating Margin | -5.6% | -153.3% |
| EPS | -7.98 | -4.47 |
| Dividend Yield | — | — |